Natural interferon-beta treatment for patients with chronic hepatitis C in Japan
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan作者机构：Department of Gastroenterology and Nephrology Chiba University Graduate School of Medicine
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2015年第7卷第8期
页 面：1125-1132页
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
基 金：Chugai Pharmaceutical MSD Tanabe-Mitsubishi Ajinomoto Bristol-Myers Squibb Daiichi-Sankyo Janssen Pharmaceutical GlaxoSmithKline Eisai AstraZeneca Daiichi Sankyo Tsumura Bayer Gilead Sciences Taiho Pharmaceutical
主 题：Hepatocellular carcinoma Hepatitis C virus Interferon-beta Interferon resistance Ribavirin
摘 要：Chronic hepatitis C virus(HCV) infection can cause liver cirrhosis and hepatocellular carcinoma(HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected patients are also getting older, and the age at HCC diagnosis has also increased. Although older HCV-infected patients have a risk of developing HCC, the treatment response to peginterferon-alpha plus ribavirin therapy is relatively poor in these patients because of drop-out or discontinuation of this treatment due to adverse events. It is established that the mechanism of action between interferon-alpha and interferon-beta is slightly different. Short-term natural interferon-beta monotherapy is effective for patients with acute hepatitis C and patients infected with HCV genotype 2 and low viral loads. Natural interferon-beta plus ribavirin for 48 wk or for 24 wk are also effective for some patients with HCV genotype 1 or HCV genotype 2. Natural interferon-beta plus ribavirin has been used for certain difficult-totreat HCV-infected patients. In the era of direct-acting anti-virals, natural interferon-beta plus ribavirin may be one of the therapeutic options for special groups of HCV-infected patients. In the near future, signal transduction pathways of interferon-beta will inform further directions.
维普期刊数据库